Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT04226456
Other study ID # CHUB-NAC
Secondary ID
Status Terminated
Phase Phase 4
First received
Last updated
Start date July 10, 2021
Est. completion date September 3, 2023

Study information

Verified date February 2023
Source Centre Hospitalier Universitaire Saint Pierre
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the efficacity of N-acetylcystein against Cisplatin-induced ototoxicity.


Description:

This is a monocentric, randomized, controlled, open label phase IV superiority trial. After signing the informed consent form and upon the confirmation of the patient eligibility, patients will be randomized 1:1 to the experimental arm (NAC + Cisplatin) or the standard arm (Cisplatin). The primary objective of this trial is to evaluate the protecting effect of Lysomucil® 10% against Cisplatin-induced ototoxicity. In this case, we will evaluate its effect through the transtympanic administration in both ears.


Recruitment information / eligibility

Status Terminated
Enrollment 19
Est. completion date September 3, 2023
Est. primary completion date May 3, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - = 18-year-old - Patients suffering from a neoplastic disease for which treatment protocol includes Cisplatin. Exclusion Criteria: - Women of childbearing potential pregnant or with intention to become pregnant within the trial duration - Women who are breastfeeding - Pathological findings on otoscopy that do not allow safe intratympanic drug delivery. - Conductive hearing loss > 20dBHL - Meniere disease - Medical history of sudden hearing loss - Sensoryneural Hearing loss (SNHL) with mean = 40dbHL Pure Tonal Audiometry (PTA)

Study Design


Intervention

Drug:
N-acetyl cysteine
Injection of a 10% solution of N-acetylcysteine through transtympanic injection in both ears

Locations

Country Name City State
Belgium CHU Saint-Pierre Brussels

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire Saint Pierre

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Apparition of ototoxicity the apparition of ototoxicity as defined by the International Common Terminology Criteria for Adverse Events (CTCAE), version 5:
A Threshold shift of 15 - 25 decibel (dB) averaged at 2 contiguous test frequencies in at least one ear
and/or the apparition of a tinnitus (not previously present).
6 month after last injection
Secondary Evaluate the apparition of ototoxicity defined by the inclusion of high frequency audiometry (Tune Grading System) the apparition of ototoxicity as defined by the International Common Terminology Criteria for Adverse Events (CTCAE), version 5:
A Threshold shift of 15 - 25 dB averaged at 2 contiguous test frequencies in at least one ear
and/or the apparition of a tinnitus (not previously present).
6 month after last injection
Secondary Hearing quality of life: Evaluation of the Impact of Hearing Loss in Adults ERSA Evaluation of the Impact of Hearing Loss in Adults (ERSA) For each question, the score of 0 means maximal difficulties, the sore of 10 means ideal situation Formulation is uniform, with no inversions: 0 always corresponds to maximal difficulty and 10 to an ideal situation, so that the lower the score the greater the impact of hearing loss on quality of life. Maximum score is 200 for respondents in work and 150 for those not in work or in retirement. 6 month after last injection
Secondary Hearing quality of life: Tinnitus Handicap Index (THI) Tinnitus Handicap Index (THI) score Range : 0 to 100. Higher scores mean a worse outcome. 6 month after last injection
See also
  Status Clinical Trial Phase
Recruiting NCT05963542 - Efficacy of Online Acceptance and Commitment Therapy and Sound Therapy for Patients With Tinnitus and Insomnia N/A
Recruiting NCT04987502 - Virtual Reality and Subjective Tinnitus N/A
Recruiting NCT04404439 - Treatment of Tinnitus With Migraine Medications Phase 4
Recruiting NCT05533840 - Establishment and Application of a New Imaging System for Otology Based on Ultra-high Resolution CT
Completed NCT03552302 - Effects of Yoga Exercise on Participates With Tinnitus
Enrolling by invitation NCT02617953 - Objective Diagnosis Method and Efficacy of Repetitive Transcranial Magnetic Stimulation as a Treatment for Tinnitus N/A
Completed NCT02974543 - Somatosensory Stimulation to Alleviate Tinnitus N/A
Completed NCT02269839 - A Feasibility Study Assessing the Effectiveness of rTMS in Tinnitus N/A
Withdrawn NCT01663467 - Efficacy of Internet and Smartphone Application-delivered Tinnitus Retraining Therapy N/A
Completed NCT01929837 - Tinnitus rTMS 2013 N/A
Completed NCT01857661 - The Influence of the Sound Generator Combined With Conventional Amplification for Tinnitus Control: Blind Randomized Clinical Trial N/A
Completed NCT01927991 - Internet-based Self-help for Tinnitus: The Role of Support N/A
Completed NCT01480193 - New Therapy for Patients With Severe Tinnitus N/A
Terminated NCT01412918 - Inhibitor Masking Device & Sodium Channel, Voltage Gated, Type IX Alpha Subunit (SCN9) Gene Expression N/A
Completed NCT00748475 - Countering Stimulus-Induced Alpha-Desynchronization to Treat Tinnitus N/A
Completed NCT00371436 - Progressive Intervention Program for Tinnitus Management N/A
Completed NCT00733044 - Cost-effectiveness of Multidisciplinary Management of Tinnitus N/A
Active, not recruiting NCT05518682 - Assessment of Bimodal Stimulation Device Compliance and Satisfaction in Individuals With Tinnitus N/A
Recruiting NCT05212298 - Effects of Herbal Sleep Formula on Patients With Insomnia and Tinnitus N/A
Completed NCT06025097 - Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus. Early Phase 1